OncomineWorld Autumn presents an all-new opportunity to learn about the latest developments in cancer genomic profiling. If you attended our May event, you were one of over 3,000 dedicated professionals who came together to advance understanding of and exchange knowledge about precision oncology research. We're back with more great programming on October 22, 2020.
What’s new to OncomineWorld Autumn?
In this virtual NGS education meeting you will be able to:
We hope you will enjoy and benefit from this meeting. We are open to any questions or feedback before, during, and after the live event.
Your Thermo Fisher Scientific Oncology NGS team
For Research Use Only. Not for use in diagnostic procedures.
José Luis Costa carried out his undergraduate studies at the University of Porto in Portugal and obtained his Ph.D. degree in Biology at Uppsala University in Sweden. Prior to joining the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) in 2006, he carried out postdoctoral research at the Vrije University Medical Center in Amsterdam, The Netherlands. He was appointed, in 2014, as Affiliated Professor at the Medical Faculty of the University of Porto. In 2020, joined Thermo Fisher Scientific as EMEA Medical Affairs Director part of the Clinical NGS and Oncology Division. Throughout his career he seeks to promote the uptake of Precision Medicine for the benefit of patients through the application of the latest technologies in the diagnosis and the search for precision therapies.
Dr. Hernández Losa is Director of Molecular Biology Laboratory in the Department of Pathology from the Vall d´Hebron Hospital in Barcelona. He has trained in Cancer Research, focusing on the signaling and virus detection pathways in FFPE human samples at the Department of Pathology in Hospital Puerta de Hierro (Madrid). After his Ph.D. in Biochemistry and Molecular Biology, he moved to Vall d´Hebron Hospital endorsing extensive experience in drug synergisms in different in vitro models of breast and pancreatic cancer, also in the field of biomarkers, being today one of the reference laboratories in Molecular Pathology. In addition in the last five years, the laboratory has validated by immunohistochemistry more than 12 prognostic and/or predictive markers of cancer. Thanks to these molecular analyzes based on real-time PCR and NGS have contributed to the selection of patients for the different clinical trials carried out at our institution. Dr. Hernández-Losa has been also involved in different technologies validation for mutational analysis of KRAS, NRAS, BRAF, PIK3CA, and EGFR genes in samples from colorectal cancer and NSCLC patients, as well as in exosome samples obtained from primary tumors.
Dr. Kletecka a board certified and fellowship trained Molecular Pathologist. She performed her residency training in anatomic and clinical pathology at Case Western Reserve University Hospitals of Cleveland and fellowship subspecialty training in Molecular Genetic Pathology and Surgical Pathology at TriCore Reference Laboratories and the University of New Mexico Hospital. She currently serves as the Medical Director of the VISN22 Molecular Diagnostics Laboratory in Los Angeles where she and her team implemented molecular oncology testing by next generation sequencing for the VA system.
Dr. Ahwon Lee is a professor of the college of medicine in the Catholic university of Korea, and a pathologist in Seoul St. Mary’s hospital who works with clinicians to find actionable mutations with various molecular biomarkers. As a pioneer of NGS routine test in Korea, she has set up and implemented comprehensive NGS tests for a solid tumor under the Korean health insurance reimbursement. She has published numbers of textbooks and scientific papers on breast pathology and gynecological oncology. Today she shares her precious experience and perspective with us about OCA Plus test.
Megan S. Lim, MD, PhD is the Director of the Division of Hematopathology, Hospital of the University of Pennsylvania, Director of the Hematopathology Fellowship Program, and the Director of the Lymphoma Biology Program at the Abramson Cancer Center. She is a Professor within the Department of Pathology and Laboratory Medicine, Dr. Lim received an MD from the University of Calgary and a PhD in Molecular Oncology from the University of Calgary and National Cancer Institute Lab of Pathology jointly. Dr. Lim obtained her Hematopathology fellowship training at the National Cancer Institute after which she assumed a faculty position at the University of Toronto (1998-2000), the University of Utah (2000-2006). the University of Michigan (2006-2015) before moving to the University of Pennsylvania in 2015. Dr. Lim is certified by the American Board of Pathology in Anatomic Pathology, with subspecialty certification in Hematopathology and Molecular Genetic Pathology. She has held numerous leadership positions and served on training and education committees for the Association of Molecular Pathology and the United States Academy of Pathology. She is a member of the Board of Directors for the United States Academy of Pathology. She is the Vice-Chair of the Non-Hodgkin Lymphoma Disease Committee of the Children’s Oncology Group and participates in integrated translational research in pediatric lymphoma. Her research interests are focused on elucidating mechanisms involved in lymphoma pathogenesis which are supported by the NIH. She has participated and directed numerous CME activities for AMP, ASCP, CAP, and the USCAP.
Alexander “Craig” Mackinnon Jr., M.D., Ph.D., is the inaugural director of the Division of Genomics Diagnostics and Bioinformatics in the Department of Pathology, School of Medicine at the University of Alabama at Birmingham. Mackinnon is leading ongoing efforts to establish the Precision Diagnostic Laboratory at UAB. A board-certified anatomical and molecular genetic pathologist, Mackinnon joined UAB after serving as associate professor in the Department of Pathology at the Medical College of Wisconsin. Mackinnon directed the Clinical and Translational Research Laboratory (CTRL) at MCW, where he provided interpretation related to the pathology of tumor samples. The lab developed multiple Next Generation Sequencing-based panels targeting variants in both DNA and RNA. He has experience designing and validating targeted, custom DNA and RNA sequencing assays. Mackinnon’s lab interpreted a range of tests, from sequencing data to digital quantitative imaging for immunohistochemical analysis. Mackinnon is a member of the College of American Pathologists and the American Society of Clinical Pathology, where he served on the Molecular Pathology Section, Pathologist Recertification Individualized Self-Assessment Examination Committee.
Dr Natalie Ngoi a medical oncologist at the National University Cancer Institute, Singapore (NCIS). Her primary clinical and research interests are in gynaecological cancers, genitourinary cancers, and precision oncology. Dr Ngoi graduated from the Yong Loo Lin School of Medicine, National University of Singapore with the degree of MBBS with Honours. She completed her Internal Medicine training at the National University Health System, Singapore and was awarded the Gordon Ransome Gold Medal in Internal Medicine. She undertook specialist training in Medical Oncology at the National University Cancer Institute, Singapore, and qualified as a Medical Oncologist in 2018. Dr Ngoi is currently an Associate Consultant in the gynaecological cancer and genitourinary cancer tumour groups at NCIS, and is an active member of the Gynecologic Cancer Group Singapore (GCGS) and Asia Pacific Gynaecologic Oncology Trials Group (APGOT). She is actively involved in the running of clinical trials at the Developmental Therapeutics Unit (NCIS), and is involved in ovarian cancer research at the Cancer Science Institute of Singapore (CSI).
Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.
After receiving her MD degree from the University of Zurich, Switzerland, Ines Raineri attended a postgraduate course for basic science at the same university. She then worked as postdoctoral fellow at the Institute for Medical Microbiology of the University of Basel, Switzerland, investigating HIV-promoter-insertions in the human genome. She received fellowships from the Swiss National Foundation, Ciba-Geigy Jubiläumsstiftung, Roche Research Foundation and Holderbank Stiftung to work as postdoctoral fellow at the University of California San Francisco, where she was later hired to work as research assistant geneticist. During her nearly 8 years at UCSF she was involved in generating transgenic cell lines and mice to study oxygen free radical metabolism. After returning to Switzerland, she worked again at the Institute for Medical Microbiology of the University of Basel, establishing knockdown systems to rapidly evaluate gene functions in embryonic stem cells. She then moved on to train as a board-certified pathologist and currently works as a staff pathologist at the Institute for Pathology medica AG in Zurich in molecular pathology, histology and cytology.
Giada Rotunno is a biotechnologist, currently researcher scientist at the University of Florence, Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM) directed by Professor AM Vannucchi. Dr. Rotunno graduated in Medical and Pharmaceutical Biotechnology in 2012 and obtained her PhD degree in Biomedical science in Experimental and Clinical Oncology at the University of Florence in 2015. Her main scientific interests concern hematological disorders with particular focus on myeloproliferative neoplasms (MPN). She is working since 2012 on the study of mutation complexity of chronic and acute myeloid neoplasms, contributing to the refinement of the risk stratification of patients with MPN. In these years, she developed the Next Generation Sequencing (NGS) techniques actually used at CRIMM center. Dr Rotunno published 45 papers on high-impact factor journals including Blood, Leukemia and other peer-reviewed journals on myeloid neoplasms.
Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events